Date: 2011-07-27
Type of information: R&D agreement
Compound: monoclonal therapeutic antibodies for the treatment of cancer
Company: Antitope (UK) University of North Carolina at Chapel Hill (USA)
Therapeutic area: Cancer Oncology
Type agreement: R&D
Action mechanism:
Disease: cancer
Details: Antitope has announced a research collaboration with the University of North Carolina at Chapel Hill, NC, USA for the generation of monoclonal therapeutic antibodies for the treatment of cancer. During the collaboration, Antitope will apply its Composite Human AntibodyTM technology to generate fully-humanized antibodies that are devoid of T cell epitopes and have a reduced risk of clinical immunogenicity.
“After discovering a novel angiogenesis factor and generating a monoclonal antibody that inhibits tumor growth in a pre-clinical model, we set out to find a company that had strong experience with humanization of monoclonal antibodies,” said Dr Nancy DeMore, Associate Professor of Surgery at the UNC School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center. “We consulted with other scientists, researched Antitope’s methods and determined that collaborating with them would be optimal.”
Financial terms:
Latest news:
